For a patient with chronic cough, negative Bravo pH monitoring, normal pulmonary function tests, completed speech‑therapy, on gabapentin (causing thick saliva), and concerned about prebiotic use, what does a negative barium swallow indicate and how should the management plan be adjusted?

Negative Barium Swallow in Chronic Cough: Management Implications

A negative barium swallow in your patient with chronic cough, negative Bravo pH monitoring, normal PFTs, and completed speech therapy indicates that structural esophageal abnormalities and aspiration are unlikely causes of the cough—you should now focus on managing unexplained chronic cough (UCC) by addressing the gabapentin-induced thick saliva side effect and considering whether the current gabapentin dose is optimized.

What the Negative Barium Swallow Rules Out

The negative barium swallow effectively excludes:

• Structural esophageal abnormalities (strictures, diverticula, masses)
• Gross aspiration as a mechanism for cough 1
• Anatomical causes of dysphagia that might contribute to cough

This is consistent with evidence showing that when chronic cough is due to gastroesophageal reflux, it typically results from distal esophageal stimulation rather than aspiration—neither bronchoscopy nor chest radiographs show aspiration patterns in these patients 1.

Current Diagnostic Status

Your patient has essentially completed the standard workup for chronic cough and meets criteria for unexplained chronic cough (UCC): cough persisting >8 weeks that remains unexplained after investigation and supervised therapeutic trials according to best-practice guidelines 2.

The negative findings include:

• Normal PFTs (rules out asthma/COPD)
• Negative Bravo pH monitoring (rules out acid GERD as primary cause)
• Negative barium swallow (rules out structural/aspiration causes)
• Completed speech therapy (first-line UCC treatment already attempted)

Critical Management Issue: Gabapentin Side Effects

The thick saliva from gabapentin is a recognized adverse effect that you must address immediately 3. The FDA labeling for gabapentin does not specifically list "thick saliva" but does note multiple CNS and systemic effects. This side effect may paradoxically worsen cough symptoms or quality of life.

Gabapentin Management Options:

1. Assess current dose and efficacy: The CHEST guideline recommends gabapentin dosing up to 1,800 mg daily in divided doses, with dose escalation starting at 300 mg once daily 2. If your patient is experiencing intolerable side effects without adequate cough control, the dose may need adjustment.

2. Risk-benefit reassessment: The guideline specifically states you should reassess the risk-benefit profile at 6 months before continuing gabapentin 2. Given the thick saliva issue, this reassessment is warranted now.

3. Consider alternative neuromodulators: If gabapentin side effects are intolerable:

   • Amitriptyline is the second most commonly used first-line agent by laryngologists (39% vs 45.1% for gabapentin) 4
   • Pregabalin is recommended in recent guidelines as an alternative 5
   • Practice patterns show that when one neuromodulator fails due to side effects, 43.9% of specialists wean and try another neuromodulator 4

Prebiotic Concerns

The patient's concern about prebiotics is relevant because:

• Prebiotics can cause gas, bloating, and altered GI motility
• While the Bravo pH monitoring was negative for acid reflux, weakly acidic and non-acidic reflux can still trigger chronic cough and are not detected by standard pH monitoring 6
• If prebiotics are causing GI symptoms or gas, they could theoretically trigger mechanoreceptor-mediated cough even without acid reflux

Recommendation: Trial discontinuation of prebiotics for 2-4 weeks to assess impact on cough, as this is a simple, reversible intervention.

Adjusted Management Plan

Immediate Actions:

1. Address gabapentin side effects:

   • If cough has improved on gabapentin: Attempt dose reduction to find the minimum effective dose that controls cough without thick saliva 4
   • If cough has NOT improved: Wean gabapentin and switch to amitriptyline (starting 10-25 mg at bedtime, titrating up) or pregabalin 5, 4

2. Discontinue prebiotics for 2-4 weeks as a therapeutic trial

3. Document baseline cough severity using a validated tool (Leicester Cough Questionnaire) to objectively measure response to interventions 7

If Cough Persists:

Since your patient has completed speech therapy once, consider:

• Repeat/intensified speech pathology therapy: The CHEST guideline suggests multimodality speech pathology therapy for UCC (Grade 2C) 2, and recent evidence shows this is often combined with neuromodulators 5
• Superior laryngeal nerve block: 24.4% of laryngologists use this when neuromodulators fail 4

Common Pitfalls to Avoid:

• Don't restart PPI therapy: With negative Bravo pH monitoring, the guideline explicitly recommends against PPI therapy (Grade 2C) 2
• Don't pursue additional structural testing: The negative barium swallow combined with negative pH monitoring makes further GI imaging low-yield
• Don't continue gabapentin indefinitely with intolerable side effects: The medication should improve quality of life, not worsen it 2, 3

Long-term Monitoring:

• Reassess in 4-6 weeks after medication adjustment
• If neuromodulator is successful, most specialists wait 3-6 months before making changes, then wean to the lowest cough-controlling dose (68.3%) 4
• If cough recurs after successful weaning, reinitiate the previously effective neuromodulator at its prior effective dose 4